Select Page

Last week, I noted how Cue Biopharma (CUE) officially entered the clinic and in turn, the Big Leagues of biotech.

Apparently, management (or the IR firm) didn’t get the memo, though.

I say that because the company held a quarterly update call Tuesday. However, there wasn’t a customary press release after the bell that covered key developments and included an optimistic quote from management. Heck, there wasn’t even a press release to remind investors about the call.

Hint: This is not the norm. And I’ll share the data to prove it in a moment.

For now, and most importantly, let’s cover the key takeaways from the call that continue to support our bullishness.

Just in case you missed it…


Want to keep reading? No problem! All you have to do is sign up for FREE here as a registered user. 

By doing so, you agree to receive periodic research updates from DTR and only DTR.

We will never rent, sell or share your info.